Press releases
-
-
-
-
-
Internal link ProQR Therapeutics Provides Update on Ophthalmic Assets
-
Internal link ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
-
-
-
-
-
-
-
-
Internal link ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
-
Internal link ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing
-
-
-
Internal link ProQR Therapeutics Added to NASDAQ Biotechnology Index
-
Internal link ProQR annonce la publication dans Nature Medicine des données du QR-110 pour l’amaurose congénitale de Leber 10
-
Internal link ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10
-
-
Internal link ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10
-
Internal link ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients
-
-